These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26219918)

  • 1. Advances in hepatitis C therapies.
    Mariño Z; Lens S; Gambato M; Forns X
    Expert Opin Pharmacother; 2015; 16(13):1929-43. PubMed ID: 26219918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.
    Childs-Kean LM; Hand EO
    Clin Ther; 2015 Feb; 37(2):243-67. PubMed ID: 25601269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report.
    Ende AR; Kim NH; Yeh MM; Harper J; Landis CS
    J Med Case Rep; 2015 Jul; 9():164. PubMed ID: 26215390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New hepatitis C therapies: the toolbox, strategies, and challenges.
    Pawlotsky JM
    Gastroenterology; 2014 May; 146(5):1176-92. PubMed ID: 24631495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of new direct acting antivirals in transplant recipients and patients with advanced disease.
    Lens S; Mariño Z; Forns X
    Dig Liver Dis; 2014 Dec; 46 Suppl 5():S197-205. PubMed ID: 25458782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis.
    Perumpail RB; Wong RJ; Ha LD; Pham EA; Wang U; Luong H; Kumari R; Daugherty TJ; Higgins JP; Younossi ZM; Kim WR; Glenn JS; Ahmed A
    Transpl Infect Dis; 2015 Apr; 17(2):275-8. PubMed ID: 25641426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir.
    Collins JM; Raphael KL; Terry C; Cartwright EJ; Pillai A; Anania FA; Farley MM
    Clin Infect Dis; 2015 Oct; 61(8):1304-6. PubMed ID: 26082511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What does the pharmacological future of treating chronic hepatitis C look like?
    Heil EL; Hynicka LM; Kottilil S; Tang L
    Expert Rev Clin Pharmacol; 2015; 8(5):605-22. PubMed ID: 26289223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety of daclatasvir for the treatment of hepatitis C.
    Jafri SM; Gordon SC
    Expert Opin Drug Saf; 2015; 14(11):1787-97. PubMed ID: 26571362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current management of hepatitis C].
    Lange CM
    Med Monatsschr Pharm; 2015 Sep; 38(9):337-44; quiz 345-6. PubMed ID: 26731851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.
    D'Ambrosio R; Aghemo A; Colombo M
    Expert Opin Drug Saf; 2015 Mar; 14(3):473-84. PubMed ID: 25645644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
    Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
    Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
    Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
    Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C treatment: an incipient therapeutic revolution.
    deLemos AS; Chung RT
    Trends Mol Med; 2014 Jun; 20(6):315-21. PubMed ID: 24636306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in the treatment of hepatitis C.
    Dhingra A; Kapoor S; Alqahtani SA
    Discov Med; 2014 Oct; 18(99):203-8. PubMed ID: 25336034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct antiviral agents for treatment-naïve patients with genotype 1 hepatitis C: A statistical model for comparing outcomes between real world and clinical trials.
    Messori A; Brunetto MR; De Luca A; Zignego AL
    Dig Liver Dis; 2015 Nov; 47(11):988-9. PubMed ID: 26205830
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful treatment of donor-derived hepatitis C infection in a lung transplant recipient.
    Theodoropoulos N; Whitson BA; Martin SI; Pouch S; Pope-Harman A
    Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28060441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late.
    Pellicelli AM; Montalbano M; Lionetti R; Durand C; Ferenci P; D'Offizi G; Knop V; Telese A; Lenci I; Andreoli A; Zeuzem S; Angelico M
    Dig Liver Dis; 2014 Oct; 46(10):923-7. PubMed ID: 24997638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of hepatitis C in a pediatric patient using simeprevir and sofosbuvir immediately after an umbilical cord blood transplantation.
    Thomas P; Santiago T; Dallas MH
    Bone Marrow Transplant; 2016 May; 51(5):735-7. PubMed ID: 26752145
    [No Abstract]   [Full Text] [Related]  

  • 20. [Hepatitis C].
    Moradpour D; Blum HE
    Ther Umsch; 2004 Aug; 61(8):493-8. PubMed ID: 15457965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.